Search

CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more

Jobs

Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Treatment for thyroid eye disease shows promise

Eight in 10 patients who received teprotumumab had a measurable reduction in symptoms

Drip

A new study published in New England Journal of Medicine has explored the effectiveness of treating thyroid eye disease using teprotumumab.
 
A total of 41 patients were given the drug while 42 received placebo.

After six weeks, 83% of patients who received teprotumumab had a measurable reduction in eye bulge compared to 10% in the placebo group.

The overall response rate in the group receiving treatment was 78% compared to 7% in the placebo group.

Those receiving teprotumumab had better outcomes in terms of quality of life and diplopia than the control group.

Teprotumumab, marketed under the brand name Trepezza, recently became the first medication to be approved for treatment of thyroid eye disease by the US Food and Drug Administration.

Dr Raymond Douglas, from Cedars-Sinai in the US, highlighted that before this development, treatment options for patients with thyroid eye disease were limited to highly invasive surgical procedures.

“This is a medical breakthrough for a very large percentage of the patient population to receive an alternative medical infusion treatment with great results, quickly,” he shared.

Image credit: Pixabay/Stux